CN103459421B - 诊断性抗体测定 - Google Patents

诊断性抗体测定 Download PDF

Info

Publication number
CN103459421B
CN103459421B CN201280013607.2A CN201280013607A CN103459421B CN 103459421 B CN103459421 B CN 103459421B CN 201280013607 A CN201280013607 A CN 201280013607A CN 103459421 B CN103459421 B CN 103459421B
Authority
CN
China
Prior art keywords
antibody
peptide
antibodies
disease
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280013607.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103459421A (zh
Inventor
M·克莱因施密特
S·席林
J-U·拉费尔德
H-U·德穆特
K·埃贝尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivorion Treatment Co ltd
Original Assignee
Probiodrug AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug AG filed Critical Probiodrug AG
Publication of CN103459421A publication Critical patent/CN103459421A/zh
Application granted granted Critical
Publication of CN103459421B publication Critical patent/CN103459421B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
CN201280013607.2A 2011-03-16 2012-03-16 诊断性抗体测定 Expired - Fee Related CN103459421B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453449P 2011-03-16 2011-03-16
US61/453,449 2011-03-16
PCT/EP2012/054629 WO2012123562A1 (en) 2011-03-16 2012-03-16 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
CN103459421A CN103459421A (zh) 2013-12-18
CN103459421B true CN103459421B (zh) 2017-07-14

Family

ID=45833428

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280013607.2A Expired - Fee Related CN103459421B (zh) 2011-03-16 2012-03-16 诊断性抗体测定

Country Status (15)

Country Link
US (2) US8809508B2 (enExample)
EP (1) EP2686346B1 (enExample)
JP (1) JP6220675B2 (enExample)
KR (1) KR102020072B1 (enExample)
CN (1) CN103459421B (enExample)
AU (1) AU2012228236B2 (enExample)
BR (1) BR112013023211B1 (enExample)
CA (1) CA2828433C (enExample)
DK (1) DK2686346T3 (enExample)
EA (1) EA032054B1 (enExample)
IL (1) IL227847A0 (enExample)
MX (1) MX343873B (enExample)
SG (1) SG192805A1 (enExample)
WO (1) WO2012123562A1 (enExample)
ZA (1) ZA201305946B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ712352A (en) 2013-03-15 2016-07-29 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
WO2016137947A1 (en) * 2015-02-24 2016-09-01 Rpeptide, Llc Anti-amyloid-beta antibodies
CN108699139B (zh) * 2015-07-16 2022-06-24 维沃永治疗公众有限公司 人源化抗体
GB201910697D0 (en) * 2019-07-26 2019-09-11 Binding Site Group Ltd Lonisation control
WO2021067565A1 (en) * 2019-10-01 2021-04-08 Repligen Corporation Determination of protein concentration in a fluid
KR102790945B1 (ko) * 2022-09-23 2025-04-04 경성대학교 산학협력단 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009987A2 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IL149976A0 (en) * 1999-12-08 2002-12-01 Mindset Biopharmaceuticals Usa Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
EP2043687A4 (en) 2006-06-29 2010-03-17 Centocor Ortho Biotech Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2008055950A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ES2468546T3 (es) 2006-11-09 2014-06-16 Probiodrug Ag Nuevos inhibidores de glutaminil ciclasa
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2118101T3 (da) 2007-03-09 2013-01-02 Probiodrug Ag IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
ES2478673T3 (es) 2007-04-18 2014-07-22 Probiodrug Ag Derivados de tioxoquinazolinona como inhibidores de la glutaminil ciclasa
DK2160380T3 (da) 2007-04-18 2014-06-30 Probiodrug Ag Cyano-guanidin derivater som glutaminyl cyclase inhibitorer
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
JP5675343B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
WO2008128981A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
JP5676249B2 (ja) 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
KR20100075639A (ko) * 2007-10-15 2010-07-02 센토코 오르토 바이오테크 인코포레이티드 인간 항-아밀로이드 항체, 조성물, 방법 및 용도
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
JP2012532094A (ja) * 2009-06-29 2012-12-13 バイオアークティック ニューロサイエンス アーベー アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009987A2 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Amino- and carboxyl-terminal heteroaeneitv of beta-amyloid peptides deposited in human brain;SAITO TAKANOMIC 等;《NEUROSCIENCE LETTERS》;19960101;第215卷(第3期);173-176 *
Apolipoprotein E co-localizes with newly formed amyloid [beta]-protein (A[beta]) deposits lacking immunoreactivity against N-terminal epitopes of A[beta] in a genotype-dependent manner;DIETMAR RUDOLF THAL等;《ACTA NEUROPATHOLOGICA》;20051101;第110卷(第5期);459-471 *
Characterization of A[beta]11-40/42 peptide deposition in Alzheimer"s disease and young Down"s syndrome brains: implication of N-terminally truncated A[beta] species in the pathogenesis of Alzheimer"s disease;KANGNING LIU 等;《ACTA NEUROPATHOLOGICA》;20060601;第112卷(第2期);163-174 *

Also Published As

Publication number Publication date
DK2686346T3 (en) 2017-03-27
EP2686346B1 (en) 2016-12-14
US9657089B2 (en) 2017-05-23
EA201301029A1 (ru) 2014-05-30
CA2828433C (en) 2020-08-04
ZA201305946B (en) 2014-10-29
AU2012228236B2 (en) 2016-10-27
KR20140006019A (ko) 2014-01-15
JP6220675B2 (ja) 2017-11-01
CN103459421A (zh) 2013-12-18
MX343873B (es) 2016-11-25
US20120237529A1 (en) 2012-09-20
US8809508B2 (en) 2014-08-19
SG192805A1 (en) 2013-09-30
JP2014509860A (ja) 2014-04-24
BR112013023211B1 (pt) 2022-11-08
NZ614217A (en) 2015-12-24
AU2012228236A1 (en) 2013-10-03
CA2828433A1 (en) 2012-09-20
BR112013023211A2 (pt) 2016-11-22
EA032054B1 (ru) 2019-04-30
WO2012123562A1 (en) 2012-09-20
EP2686346A1 (en) 2014-01-22
MX2013010571A (es) 2013-12-02
KR102020072B1 (ko) 2019-11-04
IL227847A0 (en) 2013-09-30
US20140255414A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
CN102131519B (zh) 诊断抗体测定
CN103459421B (zh) 诊断性抗体测定
HK1192568A (en) Diagnostic antibody assay
HK1192568B (en) Diagnostic antibody assay
NZ614217B2 (en) Diagnostic antibody assay
HK1158946B (en) Diagnostic antibody assay

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192568

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1192568

Country of ref document: HK

CP01 Change in the name or title of a patent holder

Address after: Halle

Patentee after: Vivorion treatment Co.,Ltd.

Address before: Halle

Patentee before: PROBIODRUG AG

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170714

CF01 Termination of patent right due to non-payment of annual fee